Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note released on Friday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners reduced their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of AWH remained flat at $0.90 during mid-day trading on Friday. 30,437 shares of the stock traded hands, compared to its average volume of 146,728. The company has a 50-day moving average price of $0.89 and a 200-day moving average price of $1.60. Aspira Women’s Health has a 52-week low of $0.74 and a 52-week high of $5.65.

Aspira Women’s Health (NASDAQ:AWH) last announced its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period last year, the business posted ($0.28) EPS. Equities research analysts forecast that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. 12.19% of the stock is owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.